Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Sunshine Heart Provides C-Pulse U.S. Clinical Update
Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced that the first two patients implanted with the C-Pulse device in April 2009 at The Ohio State University Medical Center in Columbus, Ohio have successfully completed their 3 month follow-up evaluation.
generic viagra online
MicroRNAs Hold Promise For Treating Diseases In Blood Vessels
A newly discovered mechanism controls whether muscle cells in blood vessels hasten the development of both atherosclerosis and Alzheimer"s disease, according to an article published online in the journal Nature.
News of the day
"lab-On-A-Chip" Technology Advances Colorectal Cancer Screening
According to the American Cancer Society, colorectal cancer, America"s third leading type of cancer, is also one of the most preventable. One-third of all colorectal cancer deaths could be avoided by simple screening, they say. But colonoscopies, though highly effective, can also be painful, and current diagnostic techniques are time-consuming and sometimes inaccurate.
Public Health

Roswell Park Researchers Evaluate Promising Drug For Intolerant Or Resistant CML

Roswell Park Cancer Institute (RPCI) scientists are investigating a promising drug for chronic myeloid leukemia (CML) patients who have become intolerant or resistant to standard therapies. Meir Wetzler, MD, Department of Medicine at Roswell Park Cancer Institute, analyzed the effectiveness of omacetaxine (OM) in an ongoing phase II clinical study and will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 - June 2, in Orlando, FL. "Subcutaneous Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors (TKIs): Data from an Ongoing Phase II Trial" Friday, May 29 - 5 pm EST Level 2, West Hall F1 Cancer therapies that target specific proteins have become standard treatment for patients diagnosed with chromic myeloid leukemia. A protein, BCR-ABL, causes CML cells to grow and reproduce out of control. Drugs that target BCR-ABL are known as tyrosine kinase inhibitors (TKIs). Roswell Park investigators, under the direction of Dr. Wetzler, evaluated omacetaxine in 60 patients who had failed at least two TKIs. Sixty-five CML patients participated in this phase II clinical study. Dr. Wetzler and colleagues report patients experienced treatment responses in both the white blood cells (hematologic) and the marrow cells (cytogenetic). Eighty percent of the chronic-phase patients experienced a complete hematologic response (CHR) rate and no disease progression for a median of 7.5 months. In this same group, 20% had a major cytogenetic response rate, and median response to disease progression was 2.7 months. For study patients in the accelerated phase, a 60% CHR rate was observed, with a median of 8.9 months without disease progression; and for blast phase patients, a CHR rate was 40%, with a median duration of 5.7 months. Dr. Wetzler reports that omacetaxine is generally well tolerated and that most side effects are reversible. "Targeted therapies have changed the treatment approach and improved survival rates for patients diagnosed with chronic myeloid leukemia. However, patients who develop resistance to these therapies have few options. Omacetaxine is among the next generation of novel therapies that may offer hope for those patients," said Dr. Wetzler. Roswell Park Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009